Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pennsylvania Pennsylvania Department of Health Pfizer |
---|---|
Information provided by: | University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT00596882 |
The proposed study has been designed to examine the effect of a message that primes genetic susceptibility on actual enrollment in a smoking cessation program, actual response to smoking cessation treatment, and potential moderators and mediators of this effect.
Condition | Intervention | Phase |
---|---|---|
Smoking Cessation |
Other: Message Prime |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study |
Estimated Enrollment: | 100 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
Threat only message. Participants hear information about the negative health consequences of smoking
|
Other: Message Prime
Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
Other: Message Prime
Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
|
2
Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
|
Other: Message Prime
Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
Other: Message Prime
Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
|
Despite available behavioral and pharmacological interventions to treat nicotine dependence, most smokers do not utilize these interventions. As such, the vast majority of smokers do not capitalize on potentially effective nicotine dependence treatments. The way in which health risk information is presented may influence interest in a smoking cessation program. In a series of preliminary studies, individuals provided with messages that primed the role of genetic variation in susceptibility to addiction to smoking exhibited positive consequences on intentions to quit (Cappella, Lerman, Romantan, & Baruh, 2005). The proposed study has been designed to examine the effect of a message that primes genetic susceptibility on actual enrollment in a smoking cessation program, actual response to smoking cessation treatment, and potential moderators and mediators of this effect. The results of this pilot study may provide preliminary data for a larger trial and have implications for designing interventions to promote utilization of effective treatments for nicotine dependence among smokers.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Eligible participants will be 100 male & female smokers aged 18-65, who smoke ≥ 10 cigarettes/day & who plan to live in the area for the next 6-months.
Key Exclusion Criteria Smoking Behavior
1.Use of chewing tobacco or snuff 2.Current enrollment or plans to enroll in another smoking cessation program in the next 6 months 3.Plan to use other nicotine substitutes or smoking cessation treatments in the next 6 months Alcohol/Drug Exclusion Criteria
Medication Exclusion Criteria
Current use or recent discontinuation (within last 14-days) of the following medications:
Any form of anti-psychotic medications that includes:
•antipsychotics,
•atypical antipsychotics,
•mood-stabilizers,
•anti-depressants (tricyclics, SSRI's, MAOI's),
•anti-panic agents,
•anti-obsessive agents,
•anti-anxiety agents, and
Medical Exclusion Criteria
General Exclusion
Contact: Jamie Dahm, BA | 215-746-7173 | dahmj@mail.med.upenn.edu |
Contact: Angela Pinto, MBA | 215-746-7171 | pintoa@mail.med.upenn.edu |
United States, Pennsylvania | |
Transdisciplinary Tobacco Use Research Center | |
Philadelphia, Pennsylvania, United States, 19104 |
Principal Investigator: | Robert Schnoll, Ph.D. | University of Pennsylvania |
Responsible Party: | University of Pennsylvania ( Robert Schnoll, Ph.D. ) |
Study ID Numbers: | 806910 |
Study First Received: | January 8, 2008 |
Last Updated: | January 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00596882 |
Health Authority: | United States: Institutional Review Board |
smoking cessation nicotine dependence message prime recruitment |
Nicotine polacrilex Smoking Nicotine |
Habits |